AR and prostate carcinoma: <h4>Introduction</h4>Castration-resistant prostate cancer (CRPC) is a heterogeneous and aggressive disease with limited treatment options, particularly in poorly differentiated cases that lack androgen receptor expression and progress rapidly even under conventional therapies.